Cannabis Testing Services Market Research Report 2026-2031: Profiles Agilent, Eurofins, SGS, and 18 Other Companies

Cannabis Testing Services Market Research Report 2026-2031: Profiles Agilent, Eurofins, SGS, and 18 Other Companies Dublin, Aug. 18, 2026 (GLOBE NEWSWIRE) -- The "Cannabis Testing Services - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

The global cannabis testing services market was valued at USD 359.68 million in 2025 and is expected to increase from USD 397.85 million in 2026 to USD 688.46 million by 2031. The market is projected to register a compound annual growth rate of 11.59% during the 2026-2031 forecast period.

Market expansion is being supported by wider medical and recreational cannabis legalization, stricter product safety requirements, increasing pharmaceutical-grade cannabis production and growing demand for accredited laboratory services. Commercial cannabis products typically require testing for potency, pesticides, heavy metals, residual solvents, microorganisms, mycotoxins and other regulated substances before reaching the market.

Legalization Strengthens Demand for Cannabis Testing Services

New cannabis licensing frameworks are creating immediate demand for analytical testing and Certificates of Analysis. Germany's Cannabis Act, effective from April 2024, introduced testing requirements covering pesticides, mycotoxins, heavy metals and microorganisms for cannabis social club products. The legislation has expanded the commercial role of accredited testing laboratories in one of Europe's largest economies.

Japan's amended Cannabis Control Act, enforced from December 2024, also established mandatory residual narcotic component testing for CBD-containing products. The regulatory change is increasing demand for advanced analytical capabilities, including liquid chromatography-tandem mass spectrometry. As multiple tests are commonly required for each regulated product lot, cannabis testing services can expand faster than overall production volumes in newly legalized markets.

Pharmaceutical-Grade Cannabis Production Creates Higher-Value Opportunities

The transition toward pharmaceutical-grade cannabis products is increasing demand for validated analytical methods, comprehensive documentation and specialized scientific expertise. In Brazil, pharmaceutical quality requirements associated with CBD oral solutions are supporting outsourced chromatographic and microbiological testing at accredited contract laboratories.

Emerging quality expectations for cannabis-based clinical and therapeutic products include stability testing, extractables and leachables analysis, dose uniformity and expanded contaminant screening. These requirements are expected to increase the share of higher-value pharmaceutical and research services within the cannabis testing services market.

Regulatory Fragmentation Remains a Market Restraint

Differences among state, federal and international cannabis regulations continue to increase operating complexity. In the United States, testing panels, action limits, licensing requirements and chain-of-custody procedures vary by state. Laboratories accredited in one jurisdiction may not be authorized to process samples from another jurisdiction.

The requirement for hemp laboratories to register with the U.S. Drug Enforcement Administration by December 31, 2025 adds another compliance consideration. Regulatory fragmentation can raise documentation costs, delay laboratory expansion and increase the risk associated with capital investment. High equipment costs and evolving testing standards also remain significant barriers for smaller operators.

Additional market factors include rising product recall risks linked to contaminant non-compliance, adoption of artificial intelligence-enabled laboratory information management systems for ISO/IEC 17025 workflows and continued investment in advanced analytical instrumentation.

Potency Testing Leads the Service Segment

Potency testing accounted for 68.13% of the cannabis testing services market in 2025, making it the largest service segment. Its leading position reflects mandatory cannabinoid labeling requirements across cannabis flower, concentrates, edibles, topicals and inhalable products. Repeat testing for individual commercial batches provides a consistent source of laboratory demand.

Terpene profiling is forecast to record a 13.28% CAGR through 2031, making it the fastest-growing service category. Manufacturers increasingly use terpene data for product characterization and differentiation, while clinical and consumer interest continues to expand beyond basic THC and CBD measurements.

Pesticide screening, heavy metal testing, residual solvent screening and mycotoxin testing are also expected to grow as regulators expand analyte lists and strengthen contaminant limits. Microscopy testing and other specialized services will continue supporting forensic analysis, scientific research and product verification.

Regional Cannabis Testing Services Market Outlook

North America represented 53.63% of the global market in 2025 and remained the largest regional contributor. The United States continues to generate substantial revenue through state-mandated independent laboratory testing across multiple commercial cannabis formats. Canada's March 2025 regulatory amendments increased micro-class production ceilings while maintaining comprehensive analytical testing obligations. ISO/IEC 17025 accreditation expectations and federal hemp laboratory requirements continue to support qualified testing providers.

Europe is entering a more structured stage of market development. Germany's Cannabis Act has established clearer testing requirements, while the United Kingdom, France, Italy and Spain continue to advance at different regulatory speeds. The regional outlook remains supported by tighter product controls and the gradual formalization of laboratory standards.

Asia-Pacific is forecast to grow at a 14.06% CAGR through 2031, making it the fastest-growing regional market. Japan is a major contributor following the introduction of testing requirements for CBD-containing products and stringent THC limits. Australia also supports regional demand through its medicinal cannabis testing framework. China, India and South Korea remain at earlier stages of market development, while South America, the Middle East and Africa offer longer-term potential as domestic laboratory capacity expands.

Key Topics Covered

1 Introduction

1.1 Study Assumptions & Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Cannabis Legalization Across Medical and Recreational Channels

4.2.2 Expansion of Pharmaceutical-Grade Cannabis Production

4.2.3 Higher Product Recall Risk From Contaminant Non-Compliance

4.2.4 Adoption of AI-Enabled LIMS for ISO 17025 Workflows

4.2.5 Expanding Multi-Residue Method Panels for New Cannabinoid Formulations

4.2.6 Rising Demand for Chain-of-Custody Grade Testing in Cross-Border Trade

4.3 Market Restraints

4.3.1 Fragmented State, Federal, and Cross-Border Rules

4.3.2 High Capital Cost for Advanced Analytical Instrumentation

4.3.3 Limited Standardization in Reference Materials and Methods

4.3.4 Small Lab Economics Under Pressure From Low Sample Density

4.4 Value / Supply-Chain Analysis

4.5 Regulatory Landscape

4.6 Technological Outlook

4.7 Porter's Five Forces Analysis

4.7.1 Threat of New Entrants

4.7.2 Bargaining Power of Suppliers

4.7.3 Bargaining Power of Buyers

4.7.4 Threat of Substitutes

4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts

5.1 By Service

5.1.1 Potency Testing

5.1.2 Terpene Profiling

5.1.3 Heavy Metal Testing

5.1.4 Pesticide Screening

5.1.5 Microscopy Testing

5.1.6 Residual Solvent Screening

5.1.7 Mycotoxin Testing

5.1.8 Other Cannabis Testing Services

5.2 By End Use

5.2.1 Independent Testing Laboratories

5.2.2 Pharmaceutical & Research Institutes

5.2.3 Other End Users (Cannabis Dispensaries, Cannabis Cultivators and Growers, etc.)

5.3 By Geography

5.3.1 North America

5.3.1.1 United States

5.3.1.2 Canada

5.3.1.3 Mexico

5.3.2 Europe

5.3.2.1 Germany

5.3.2.2 United Kingdom

5.3.2.3 France

5.3.2.4 Italy

5.3.2.5 Spain

5.3.2.6 Rest of Europe

5.3.3 Asia-Pacific

5.3.3.1 China

5.3.3.2 Japan

5.3.3.3 India

5.3.3.4 Australia

5.3.3.5 South Korea

5.3.3.6 Rest of Asia-Pacific

5.3.4 Middle East & Africa

5.3.4.1 GCC

5.3.4.2 South Africa

5.3.4.3 Rest of Middle East & Africa

5.3.5 South America

5.3.5.1 Brazil

5.3.5.2 Argentina

5.3.5.3 Rest of South America

6 Competitive Landscape

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles (includes Global Level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)

6.3.1 Adact Medical Ltd.

6.3.2 Agilent Technologies, Inc.

6.3.3 AZ Biopharm GmbH

6.3.4 BRITISH CANNABIS

6.3.5 CW Analytical

6.3.6 Eurofins Scientific SE

6.3.7 GreenLeaf Lab

6.3.8 Kaycha Labs

6.3.9 Laboratorium Dr. Liebich

6.3.10 PerkinElmer Inc.

6.3.11 PharmLabs LLC

6.3.12 PhytoVista Laboratories

6.3.13 Praxis Laboratory

6.3.14 ProVerde Laboratories

6.3.15 Saskatchewan Research Council

6.3.16 SC Labs

6.3.17 SGS Societe Generale de Surveillance SA

6.3.18 Shimadzu Corporation

6.3.19 Steep Hill, Inc.

6.3.20 Thermo Fisher Scientific Inc.

6.3.21 Waters Corporation

7 Market Opportunities & Future Outlook

7.1 White-space & Unmet-need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/1t0eb3

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.